Herceptin's selling about $5 billion and T-DM1 should replace Herceptin almost completely in a matter of a few years after the initial approval. I also believe that Takeda may make more then you're figuring from your analysis of SGN-35, so IMGN should make more over time.
As to the argument about who's technology's best, I've yet to see positive data from SGEN in solid tumors. I also believe that IMGN has many more drugs in trials and coming into trials. Compare the pipelines. SGEN has by far led the PR war, but IMGN has numerous linkers, numerous effector molecules, and moderate success to date with its roughly 15 year old technology in N901-DM1, essentially its earliest version of TAP Technology.
To date it's latest generation linkers and effector molecules have yet to be discussed even in preclinical drugs. It may be years before we really know what their technology can do. I suspect that one reason drug trials have been delayed is to permit partners to try the latest and greatest with their MAB's as all partners have access to the linkers, but only SNY has access to effector molecules other than the DMx family.
Gary
